Eplerenone for chronic central serous chorioretinopathy - Authors' reply

Lancet. 2020 Nov 14;396(10262):1557-1558. doi: 10.1016/S0140-6736(20)32321-7.

Authors

Andrew Lotery¹, Abby O'Connell², Rosie A Harris², Sobha Sivaprasad³, Barnaby C Reeves²

Affiliations

¹ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK. Electronic address: a.j.lotery@soton.ac.uk.
² Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical School, University of Bristol, Bristol Royal Infirmary, Bristol, UK.
³ NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital National Health Service Foundation Trust, London, UK.

PMID: 33189170
DOI: 10.1016/S0140-6736(20)32321-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Central Serous Chorioretinopathy* / diagnosis
Central Serous Chorioretinopathy* / drug therapy
Eplerenone
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use
Spironolactone / therapeutic use

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone
Eplerenone

Grants and funding

MC_PC_16004/MRC_/Medical Research Council/United Kingdom